Skip to main content
Alphamab Oncology logo

Alphamab Oncology — Investor Relations & Filings

Ticker · 9966 ISIN · KYG0330A1013 LEI · 254900VOW925DTFGNA02 HKEX Manufacturing
Open in API
Filings indexed 368 across all filing types
Latest filing 2020-12-23 Regulatory Filings
Country KY Cayman Islands
Listing HKEX 9966

About Alphamab Oncology

http://www.alphamabonc.com

Alphamab Oncology is an innovative biopharmaceutical company specializing in the research, development, and commercialization of differentiated anti-tumor biotherapeutics. The company is dedicated to addressing unmet clinical needs in oncology by developing effective, safe, and globally competitive cancer therapies. A core unique selling point is its proprietary technology platform for Antibody-Drug Conjugates (ADCs). This platform utilizes site-specific conjugation via Fc glycan, employing a one-enzyme, two-step process to produce ADCs with a highly uniform Drug-to-Antibody Ratio (DAR). This method results in superior serum stability and enhanced bystander killing effect, aiming to widen the therapeutic window and minimize toxic side effects. Key pipeline assets include KN035 and the biparatopic HER2-targeting ADC, JSKN003, which has received Breakthrough Therapy Designation from the FDA.

Recent filings

Filing Released Lang Actions
VOLUNTARY ANNOUNCEMENT - THE COMBINATION THERAPY OF KN026 AND KN046 WAS GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the FDA granting Orphan Drug Designation to a combination therapy. It contains detailed information about the drug candidates, clinical trials, regulatory approvals, and company background. There are no financial statements, earnings data, or management discussion of financial results. The document is not a report but an announcement of a business development event related to drug designation by the FDA. It does not fit categories like Annual Report, Earnings Release, or Regulatory Filings related to financial compliance. It is a voluntary announcement about a significant business advancement, which aligns best with the Regulatory Filings (RNS) category as a general regulatory announcement that does not fit other specific categories.
2020-12-23 English
VOLUNTARY ANNOUNCEMENT - BLA ACCEPTED BY THE NMPA FOR KN035 IN THE TREATMENT OF MSI-H/DMMR SOLID TUMORS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding the acceptance of a Biologic License Application (BLA) by the National Medical Products Administration (NMPA) for a drug candidate KN035. It provides detailed information about the drug, clinical trial results, company background, and related partnerships. The document is not a full financial report, audit, or earnings release. It is not a regulatory filing in the sense of compliance or officer certification, nor is it a report publication announcement. The content focuses on a business development update related to drug approval and clinical progress, which fits best under a general regulatory announcement category. Given the nature and content, the most appropriate classification is Regulatory Filings (RNS), which serves as a fallback for miscellaneous announcements that do not fit other specific categories.
2020-12-21 English
CHANGE OF JOINT COMPANY SECRETARY AND AUTHORIZED REPRESENTATIVE AND TERMINATION OF THE ENGAGEMENT OF THE CHIEF FINANCIAL OFFICER AND THE BOARD SECRETARY
Board/Management Information Classification · 100% confidence The document is an announcement from Alphamab Oncology regarding changes in key company personnel: termination of the Chief Financial Officer and Board Secretary, and appointment of a new joint company secretary and authorized representative. It includes biographical details of the new appointee and references compliance with listing rules. There is no financial data, report, or detailed analysis present. The document is clearly about management changes at the board and senior management level. Therefore, it fits the category of Board/Management Information (MANG). The document length is 4136 characters, which is relatively short and consistent with an announcement rather than a full report.
2020-12-07 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2020
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 30/11/2020, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in share capital and securities issued during the month, including confirmations related to the issuance and listing conditions. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting monthly share capital movements to the stock exchange, consistent with a regulatory compliance announcement rather than a financial report or announcement of a report. Therefore, it fits best under Regulatory Filings (RNS).
2020-12-04 English
Next Day Disclosure Return
Regulatory Filings Classification · 95% confidence The document is a Next Day Disclosure Return for a Main Board listed issuer, Alphamab Oncology, detailing changes in issued share capital and share buybacks. It includes specific data on share issues pursuant to employee share options and confirms compliance with listing rules and legal requirements. The document is a regulatory disclosure about share capital changes and repurchases, not a full financial report or earnings release. It is a formal regulatory filing required by the stock exchange to disclose capital changes and share buybacks. The document length (8986 characters) and content indicate it is not a brief announcement but a detailed regulatory disclosure. Therefore, it fits best under the category of Regulatory Filings (RNS), as it does not match other more specific categories like Share Issue/Capital Change (SHA) or Transaction in Own Shares (POS) which typically focus on announcements rather than detailed regulatory returns. Hence, the classification is RNS with high confidence.
2020-11-17 English
VOLUNTARY ANNOUNCEMENT - ABSTRACTS ON PRELIMINARY POSITIVE RESULTS FROM THE COMBINATION THERAPY OF KN026 AND KN046 FOR POSTER PRESENTATION AT SITC 2020
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Alphamab Oncology regarding preliminary positive clinical trial results for a combination therapy (KN026+KN046). It details clinical trial data, future trial plans, and drug development status. There is no indication that this is a full financial report, audit, earnings release, or regulatory filing. The document is not a transcript, nor does it announce voting results, capital changes, or management changes. It is a business update on clinical progress and drug development, typical of a voluntary announcement to shareholders and investors. The document length is over 10,000 characters, so it is not a brief report publication announcement. The content is focused on clinical trial results and business progress rather than financials or governance. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-11-10 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.